Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar（rh Recombined Endostatin）With Single Docetaxel In NSCLC Patients

NCT00813332 is registered in ClinicalTrials.gov with Simcere Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT00813332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00813332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar（rh Recombined Endostatin）With Single Docetaxel In NSCLC Patients
Lead sponsor
Simcere Pharmaceutical Co., Ltd
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2008
Completion date
October 31, 2010
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc, recurrent nsclc